233 related articles for article (PubMed ID: 29139041)
1. Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with Polypharmacy.
Müller-Rebstein S; Trenkwalder C; Ebentheuer J; Oertel WH; Culmsee C; Höglinger GU
CNS Drugs; 2017 Dec; 31(12):1093-1102. PubMed ID: 29139041
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacotherapy of Parkinson's disease : Aspects of drug safety].
Müller-Rebstein S; Trenkwalder C; Oertel WH; Culmsee C; Eckermann G; Höglinger GU
Nervenarzt; 2017 Aug; 88(8):888-894. PubMed ID: 28497256
[TBL] [Abstract][Full Text] [Related]
3. Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.
Klietz M; Greten S; Wegner F; Höglinger GU
Drugs Aging; 2019 Jun; 36(6):511-530. PubMed ID: 30937878
[TBL] [Abstract][Full Text] [Related]
4. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention.
Grandas F; Hernández B;
Eur J Neurol; 2007 Mar; 14(3):282-9. PubMed ID: 17355548
[TBL] [Abstract][Full Text] [Related]
5. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
Jankovic J; Stacy M
CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
[TBL] [Abstract][Full Text] [Related]
6. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
7. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study.
Durif F; Devaux I; Pere JJ; Delumeau JC; Bourdeix I;
Eur Neurol; 2001; 45(2):111-8. PubMed ID: 11244274
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta-Analysis.
Li J; Lou Z; Liu X; Sun Y; Chen J
Eur Neurol; 2017; 78(3-4):143-153. PubMed ID: 28813703
[TBL] [Abstract][Full Text] [Related]
11. Prescription of drugs with potential adverse effects on cardiac conduction in Parkinson's disease.
Malek NM; Grosset KA; Stewart D; Macphee GJ; Grosset DG
Parkinsonism Relat Disord; 2013 Jun; 19(6):586-9. PubMed ID: 23522959
[TBL] [Abstract][Full Text] [Related]
12. Freezing of gait in patients with advanced Parkinson's disease.
Giladi N; Treves TA; Simon ES; Shabtai H; Orlov Y; Kandinov B; Paleacu D; Korczyn AD
J Neural Transm (Vienna); 2001; 108(1):53-61. PubMed ID: 11261746
[TBL] [Abstract][Full Text] [Related]
13. Anticholinergic burden in Parkinson's disease inpatients.
Lertxundi U; Isla A; Solinis MA; Domingo-Echaburu S; Hernandez R; Peral-Aguirregoitia J; Medrano J
Eur J Clin Pharmacol; 2015 Oct; 71(10):1271-7. PubMed ID: 26254777
[TBL] [Abstract][Full Text] [Related]
14. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Goetz CG; Stebbins GT; Blasucci LM
Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
[TBL] [Abstract][Full Text] [Related]
15. Drug safety profiles in geriatric patients with Parkinson's disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis.
Greten S; Müller-Funogea JI; Wegner F; Höglinger GU; Simon N; Junius-Walker U; Gerbel S; Krause O; Klietz M
J Neural Transm (Vienna); 2021 Jan; 128(1):49-60. PubMed ID: 33263172
[TBL] [Abstract][Full Text] [Related]
16. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
Ceballos-Baumann A; Häck HJ
Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
[TBL] [Abstract][Full Text] [Related]
17. Prescribing patterns of antiparkinson drugs in a group of Colombian patients, 2015.
Machado-Alba JE; Calvo-Torres LF; Gaviria-Mendoza A; Castrillón-Spitia JD
Biomedica; 2018 Sep; 38(3):417-426. PubMed ID: 30335247
[TBL] [Abstract][Full Text] [Related]
18. Intrajejunal levodopa infusion in advanced Parkinson's disease: long-term effects on motor and non-motor symptoms and impact on patient's and caregiver's quality of life.
Fasano A; Ricciardi L; Lena F; Bentivoglio AR; Modugno N
Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):79-89. PubMed ID: 22338551
[TBL] [Abstract][Full Text] [Related]
19. Locomotor response to levodopa in fluctuating Parkinson's disease.
Moore ST; MacDougall HG; Gracies JM; Ondo WG
Exp Brain Res; 2008 Feb; 184(4):469-78. PubMed ID: 17828529
[TBL] [Abstract][Full Text] [Related]
20. Subthalamic nucleus stimulation for Parkinson disease: benefits observed in levodopa-intolerant patients.
Katayama Y; Kasai M; Oshima H; Fukaya C; Yamamoto T; Ogawa K; Mizutani T
J Neurosurg; 2001 Aug; 95(2):213-21. PubMed ID: 11780890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
